Last updated 54 days ago

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

84 patients around the world

Available in Chile, United States

The study duration per participant will be up to 116 weeks.

Sanofi

1Research sites

84Patients around the world

This study is for people with

Hidradenitis suppurativa

Requirements for the patient

To 70 Years

All Gender

Medical requirements

Sites

Clínica Dermacross S.A. - Vitacura - Santiago

Recruiting

Av. Manquehue Norte 2051 C, Vitacura, Metropolitana, 7640881dermacross.cl

SponsorSanofi

Conditions

Requirements

To 70 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06118099